Current and emerging treatment options in the management of advanced ovarian cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63(1):11–30.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Human Pathol. 2011;42:918–931.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–1244.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Dubois A, McAlpine J, et al First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21:756–762.
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–1338.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Isonishi S, et al. Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–1026.
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014 Apr;15(4):396–405.
   PubMed Web of Science ®Google Scholar
• Chan J, Brady MF, Penson RT, et al. Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin ± bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). Int J Gynecol Cancer. 2013;23(8 suppl 1):9–10.
   PubMed Web of Science ®Google Scholar
• Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943–953.
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Canncer. 2011 Sep 23;11(10):719–725.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Groen RS, Gershenson DM, Fader AN. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. Gynecol Oncol. 2015 Feb;136(2):373–383.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384(9951):1376–1388.
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–2483.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–2496.
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
   PubMed Web of Science ®Google Scholar
• Randall LM, Burger RA, Nguyen H, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol Oncol. 2013;130(1):e33–e34.
   Google Scholar
• Coleman RL, Burger RA, Brady MA, et al. Analysis of survivorship in high-risk patients on treated on GOG-218. Gynecol Oncol. 2013;130:e112–13.
   Google Scholar
• Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14(3):236–243.
   PubMed Web of Science ®Google Scholar
• Winterhoff BJN, Kommoss S, Oberg AL, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol. 2014;32:5s. (suppl; abstr 5509).
   Web of Science ®Google Scholar
• Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol. 2014;32:5s. (suppl; abstr 5502).
   Web of Science ®Google Scholar
• Oza AM, Selle F, Davidenko I, et al. Safety and efficacy in ROSIA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). ECCO 2015 meeting. 2015. Abstract 2702
   Google Scholar
• Gonzalez-Martin A, Gladieff L, Tholander B, et al. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer. 2013;49(18):3831–3838.
   PubMed Web of Science ®Google Scholar
• Korach J, Colombo N, Davidenko I, et al. Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): the ROSiA experience. J Clin Oncol. 2013;31:(suppl; abstr 5541).
   Web of Science ®Google Scholar
• Garcia Y, De Juan A, Mendiola C, et al. Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL). J Clin Oncol. 2015;33:(suppl; abstr 5531).
   Google Scholar
• Du Bois A, Floquet A, Jw K, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–3382.
   PubMed Web of Science ®Google Scholar
• Nomura H, Hanker L, Fabbro M, et al. Pazopanib versus placebo in women without progression after first-line chemotherapy for advanced epithelial ovarian, POSTER 880PD fallopian tube, or primary peritoneal cancer (AEOC): second interim overall survival analysis from the AGO-OVAR16 trial. Ann Oncol. 2014;25(suppl_4):iv305–iv326. doi:10.1093/annonc/mdu338.
   Google Scholar
• Herzog TJ, Scambia G, Kim B-G, et al. A randomized phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma. Gynecol Oncol. 2013;130:25–30.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol Cancer. 2013;23(8Suppl 1):7–8.
   Google Scholar
• Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–248.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Bradya B MF, Herzog TJ, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Presented at: Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer 2015; 2015 Mar 28–31; Chicago, IL. Abstract 3.
   Google Scholar
• Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601–5606.
   PubMed Web of Science ®Google Scholar
• Hirte H, Lheureux S, Fleming GF, et al. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015 Jul;138(1):55–61.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Perren T, Raja FA et al: Randomised doubleblind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Program and abstracts of the European Cancer Congress, September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract LBA 10, 2013.
   Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308.
   PubMed Web of Science ®Google Scholar
• Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;1;32(13):1309–1316.
   PubMed Web of Science ®Google Scholar
• Poveda AM, Selle F, Hilpert F et al. Weekly paclitaxel, pegylated liposomal doxorubicin or topotecan 6 bevacizumab in platinum-resistant ovarian cancer: analysis by chemotherapy cohort in the GCIG AURELIA randomised phase III trial [abstract LBA26]. Presented at: European Society of Medical Oncology congress; Sep 28–Oct 2, 2012; Vienna, Austria
   Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:799–808.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: results from the phase III TRINOVA-1 study. J Clin Oncol. 2015;33:15. supple; abstr 5503.
   Web of Science ®Google Scholar
• Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561–568.
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group study. Ann Oncol. 2011;22(2):335–340.
   PubMed Web of Science ®Google Scholar
• Baumann KH, Du Bois A, Meier W, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. 2012;23(9):2265–2271.
   PubMed Web of Science ®Google Scholar
• Campos SM, Penson RT, Matulonis U, et al. A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013;128(2):215–220.
   PubMed Web of Science ®Google Scholar
• Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011;29(1):69–75.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Thompson DS, Bismayer JA, et al. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute. Cancer Med. 2015;5:673–681.
   Web of Science ®Google Scholar
• Schwandt A, Von Gruenigen VE, Wenham RM, et al. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Invest New Drugs. 2014;32(4):729–738.
   PubMed Web of Science ®Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709–3714.
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2011;29:(suppl; abstr 5008).
   Web of Science ®Google Scholar
• Oaknin A, Floquet A, Le Tourneau C, et al. Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): results from a single arm extension phase of the phase I FIH study. J Clin Oncol. 2015;33:(suppl; abstr 5549).
   Web of Science ®Google Scholar
• Coleman RL, Duska LR, Ramirez PT, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011;12:1109–1117.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill M, Walker JL, et al. Randomized phase 2 evaluation of bevacizumab versus bevacizumab/fosbretabulin in recurrent ovarian, tubal or peritoneal carcinoma: a gynecologic oncology group study. Presented at: 2015 Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer; 2015 Mar 28–31; Chicago, IL. Seminal Abstract 4.
   Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785–3790.
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–251.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–861.
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372–379.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–1392.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–861.
   PubMed Web of Science ®Google Scholar
• L’heureux S, Ledermann JA, Kaye SB, et al. Characterization of ovarian cancer long-term responders on olaparib. J Clin Oncol. 2014;32:359s. suppl 15s; abstr 5534.
   Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–250.
   PubMed Web of Science ®Google Scholar
• Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16:87–97.
   PubMed Web of Science ®Google Scholar
• Chan N, Bristow RG. “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res. 2010;16(18):4553–4560.
   PubMed Web of Science ®Google Scholar
• Liu J, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet. 2014;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Matulonis U, Wulf G, Barry W et al. Phase I of oral BKM120 or BYL719 and olaparib for high grade serous ovarian cancer or triple negative breast cancer: final results of the BKM120 plus olaparib cohort. AACR Annual Meeting 2015. Abstract 8972
   Google Scholar
• Swisher EM, Oza AM, Coleman RL, et al. Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: interim results for ARIEL2 clinical trial. Gynecol Oncol. 2015. doi:10.1016/j.ygyno.2015.04.024.
   Google Scholar
• Kristeleit R, Swisher E, Oza A, et al. Final results of ARIEL2 (Part 1): a phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis. Presented at the 2015 European Cancer Congress (ECC); 2015 Sep 29; Vienna. Abstract #2700.
   Google Scholar
• Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–892.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Mina LA, Gonzalez M, et al. First-inhuman trial of the novel PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol. 2013;31: [Suppl.; abstr 2580].
   Google Scholar
• Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;137(3):386–391.
   PubMed Web of Science ®Google Scholar
• Kummar S, Oza AM, Fleming GF, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015;1;21(1):68–76.
   PubMed Web of Science ®Google Scholar
• Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8:2992–3000.
   PubMed Web of Science ®Google Scholar
• Oza AM, Weberpals JI, Provencher DM, et al. An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer. J Clin Oncol. 2015;33:(suppl; abstr 5506).
   PubMed Web of Science ®Google Scholar
• Coleman RL, Roszak A, Behbakht K. Randomized phase 2 study of investigational, selective Aurora A kinase inhibitor alisertib (MLN8237) with weekly paclitaxel vs paclitaxel alone in patients with recurrent ovarian cancer. Ann Oncol. 2014;25(suppl_4):iv305–iv326. doi:10.1093/annonc/mdu338.
   Google Scholar
• Vergote I, Armstrong D, Scambia G, et al. Phase III double-blind, placebo-controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum-sensitive ovarian cancer in first relapse. Int J Gynecol Cance. 2013;23(8Suppl 1):11.
   Google Scholar
• Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31:4400–4406.
   PubMed Web of Science ®Google Scholar
• More KN, Lainie PM, Seward SM, et al. Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. J Clin Oncol. 2015;33: (suppl; abstr 5518).
   Web of Science ®Google Scholar
• Takano M, Sugiyama T, Yaegashi N, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan clear cell carcinoma study. Int J Gynecol Cancer. 2008;18:937–942.
   PubMed Web of Science ®Google Scholar
• Tan DSP, Miller RE, Kaye SB. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer. 2013;108:1553–1559.
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Kawase C, Altomare DA, et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 2010 Aug;9(8):2411–2422.
   PubMed Web of Science ®Google Scholar
• Chana J, Bradyb WE, Brownc J, et al. A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2015;138S1. doi:10.1016/j.ygyno.2015.04.021.
   Google Scholar
• Frumovitz M, Schmeler KM, Malpica A, et al. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010 Jun;117(3):491–496.
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, et al Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283–290.
   PubMed Web of Science ®Google Scholar
• Anglesio MS, Kommoss S, Tolcher M, et al Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111–120.
   PubMed Web of Science ®Google Scholar
• Gore ME, Hackshaw A, Brady WE, et al. Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer. J Clin Oncol. 2015;33:(suppl; abstr 5528).
   Web of Science ®Google Scholar
• Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114(1):48–52.
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012 Jun;125(3):661–666.
   PubMed Web of Science ®Google Scholar
• Singer G, Kurman RJ, Chang H-W, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223–1228.
   PubMed Web of Science ®Google Scholar
• Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134–140.
   PubMed Web of Science ®Google Scholar
• The UK Clinical Research Network Study Portfolio. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12071
   Google Scholar
• Grisham RN, Iyer G, Sala E, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int J Gynecol Cancer. 2014;24(6):1010–1014.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105:3005–3010.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, et al. Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab. J Clin Oncol. 2015;33:(suppl; abstr 5570).
   PubMed Web of Science ®Google Scholar
• Varga A, Piha-Paul SA, Ott PA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J Clin Oncol. 2015;33:(suppl; abstr 5510).
   Google Scholar
• Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. J Clin Oncol. 2015;33:(suppl; abstr 5509).
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Karkada M, Oza AM, et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology 2015;May74(8):e1026529. eCollection 2015 Aug.
   PubMed Web of Science ®Google Scholar
• Villella JA, Wilson MK, Berinstein NL, et al. Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer. J Clin Oncol. 2015;33:(suppl; abstr 3072).
   Web of Science ®Google Scholar